Kodiak Sciences Inc. (KOD) Investor Relations Documents

Kodiak Sciences Inc. (KOD) investor relations documents from the company's IR site: 15 presentations, 25 press releases; latest deck 2026-06-04. Read in-app with summaries. First-party data.

View Presentation — Kodiak Sciences is a clinical-stage vision company advancing three Phase 3 retinal assets, with four topline data readouts and three BLA filings expected by 2027.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-13Press releasePDF Version
2026-08-13Press releaseKodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
2026-08-10Press releasePDF Version
2026-08-10Press releaseKodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macu
2026-08-06Press releasePDF Version
2026-08-06Press releaseKodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Seco
2026-06-04PresentationView Presentation
2026-06-04PresentationDownload
2026-05-28Press releasePDF Version
2026-05-28Press releaseKodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
2026-05-07Press releasePDF Version
2026-05-07Press releaseKodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
2026-05-01Press releasePDF Version
2026-05-01Press releaseKodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertia
2026-03-31Press releasePDF Version
2026-03-31Press releaseKodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
2026-03-26Press releasePDF Version
2026-03-26Press releaseKodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstra
2026-02-05PresentationKSI-101: APEX end-of-study results in MESI
2026-02-05PresentationView Presentation
2026-02-04Press releasePDF Version
2026-02-04Press releaseFinal APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at
2026-01-12PresentationView Presentation
2026-01-07Press releasePDF Version
2026-01-07Press releaseKodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
2025-11-17PresentationView Presentation
2025-09-13PresentationView Presentation
2025-09-04PresentationView Presentation
2025-08-19PresentationView Presentation
2025-07-16PresentationView Presentation
2025-06-26PresentationView Presentation
2025-03-27Press releaseKodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
2025-02-07PresentationGlaucoma 360 New Horizons Forum 2025
2025-01-15PresentationView Presentation
2024-11-14Press releaseKodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results
2024-08-14Press releaseKodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results
2024-06-08PresentationView Presentation
2024-05-15Press releaseKodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
2024-02-13Press releaseKodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
2024-02-03PresentationView Presentation

KOD overview · KOD earnings · KOD financials · KOD KPIs · KOD ownership · KOD peers · KOD filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.